Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02435914 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 236
- Enrollment target
NCT02435914 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 236 participants.
The verdict
NCT02435914, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 236 participants
- Enrollment target
Study Summary
This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of 3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle in patients with dry eye disease.
Interventions
- DRUG AGN-223575 ophthalmic solution
- DRUG AGN-223575 vehicle ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02435914
The ClinicalTrials.gov registry entry for NCT02435914 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGN-223575 ophthalmic solution is the first listed.
NCT02435914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02435914 about?
NCT02435914 is a clinical study titled "Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease". This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of 3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle in patients with dry eye disease.
What is the current status of trial NCT02435914?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2015-06. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02435914?
The interventions under investigation include: AGN-223575 ophthalmic solution (DRUG), AGN-223575 vehicle ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02435914?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.